Recently Lumír Kunovský, Associate Professor at the University Hospital Brno, shared a post on X about a recent paper by Kasper Overbeek et al. titled “Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment” published in CGH:
Lumír Kunovský commented on X sharing the paper:
“Pancreas2000 project.
- Type 1 Autoimmune Pancreatitis in Europe
- Clinical Profile and Response to Treatment
in Clinical Gastroenterology and Hepatology (CGH)
EPC2024
Date: June 26-29, 2024
Figure 1
Complete remission stratified on elevation of IgG4 level.
Remission stratified for the different steroid remission induction treatment or no treatment.
- Complete remission: absence of clinical symptoms and resolution of radiologic abnormalities attributed to AIP.
- Partial remission: either absence of symptoms or resolution of radiol abnormal.
Conclusions
- Patients with type 1 AIP and elevated IgG4 level may need closer monitoring.
- For remission induction, a starting dose of 0.4 mg/kg/day for 2 weeks followed by a short taper period seems effective.”
Source: Lumír Kunovský/X